IP Library Granted Patent US 8,349,820
Granted Patent B2
US 8,349,820 · App. 11/873,595 · Granted Jan 8, 2013

Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido

Assignee: Bayer Pharma Aktiengesellschaft
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,349,820
App. No.
11/873,595
Granted
Jan 8, 2013
Kind
B2
Abstract

The invention relates to the use, optionally together with oral contraception, of estradiol valerate or 17β-estradiol in combination with 17α-cyanomethyl-17-β-hydroxyestra-4,9-dien-3-one (dienogest) in a multistage or single-stage combination preparation for oral therapy to maintain and/or increase feminine libido. The total number of daily dose units of the multistage combination and of a pharmaceutically harmless placebo or a single-stage combination and optionally the pharmaceutically harmless placebo-containing or placebo- and hormone-free daily dose units amounts to 28 daily dose units.

Claims (18)

1. A method for maintaining or increasing feminine libido comprising orally administering to a woman

one oral dosage unit comprising 3 mg of estradiol valerate daily for 2 days,

then one oral dosage unit comprising 2 mg of estradiol valerate and 2 mg of dienogest daily for 5 days,

then one oral dosage unit comprising 2 mg of estradiol valerate and 3 mg of dienogest daily for 17 days,

then one oral dosage unit comprising 1 mg of estradiol valerate daily for 2 days, and

then one oral dosage unit comprising a pharmaceutically acceptable placebo daily for 2 days,

wherein the woman's libido is maintained or increased.

2. A method of claim 1 wherein the woman's libido is increased.

3. A method of claim 1 wherein the woman's libido is maintained.

4. A method for oral contraception and maintaining or increasing feminine libido comprising orally administering to a woman

one oral dosage unit comprising 3 mg of estradiol valerate daily for 2 days,

then one oral dosage unit comprising 2 mg of estradiol valerate and 2 mg of dienogest daily for 5 days,

then one oral dosage unit comprising 2 mg of estradiol valerate and 3 mg of dienogest daily for 17 days,

then one oral dosage unit comprising 1 mg of estradiol valerate daily for 2 days, and

then one oral dosage unit comprising a pharmaceutically acceptable placebo daily for 2 days,

wherein the woman's libido is maintained or increased.

5. A method of claim 4 wherein the woman's libido is increased.

6. A method of claim 4 wherein the woman's libido is maintained.

Assignments (5)
CHANGE OF NAME Recorded Jul 1, 2013
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 030719/0474 →
CHANGE OF NAME Recorded Nov 14, 2012
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 029293/0348 →
CHANGE OF NAME Recorded Nov 11, 2012
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 029277/0286 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2008
From: ZEUN, SUSAN; ZIMMERMANN, HOLGER; PARKE, SUSANNE
To: BAYER SCHERING PHARMA AG
Reel/Frame 020501/0817 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2007
From: ZEUN, SUSAN
To: BAYER SCHERING PHARMA AG
Reel/Frame 020117/0170 →
Priority Claims (2)
EP 06022091 · Oct 20, 2006 · regional
EP 07009373 · May 10, 2007 · regional
Continuity (2)
Provisional Application 60917154 · May 10, 2007
Related Publication 20080125401A1 · May 29, 2008